Incentive Programs

Option Program 2023/2025

The 2023 AGM resolved to approve the Board’s proposal regarding the implementation of a long-term incentive program in the form of an option program comprising all employees and other key persons in the company. The option program comprise a maximum of 817,500 stock options and the participants may be allotted options free of charge based on performance and continued employment. Each option entitles the holder to subscribe for one new share in BioInvent during the period from the day of release of the company’s year-end report for the financial year 2025 up to and including 28 February 2027. The subscription price per share shall be SEK 34.91. 

Options granted vested by 1/3 during each of the financial years 2023, 2024 and 2025, based on performance and continued employment with, or assignment for, BioInvent. The performance criteria for vesting will be based on the same criteria as for management’s annual bonus, which principally are based on fixed technical milestone-criteria in projects, criteria for development of the project portfolio and other pre-determined criteria attributable to the business. 

To enable the company’s delivery of shares pursuant to the option program and to secure costs connected therewith, primarily social security charges, the AGM resolved on a directed issue of maximum of 948,300 warrants, and approval of transfer of warrants. If fully exercised, Option Program 2023/2025 will represent a dilution of 0.9 percent of the shares in the Company. Vesting in 2023 amounted to 206,629 options. Vesting in 2024 amounted to 177,040 options. Vesting in 2025 amounted to 146,853 options. As of December 31, 2025, 512,006 stock options were outstanding.
 

Option Program 2024/2026

The 2024 AGM resolved to approve the Board’s proposal regarding the implementation of a long-term incentive program in the form of an option program comprising all employees and other key persons in the company. The option program comprise a maximum of 890,000 stock options and the participants may be allotted options free of charge based on performance and continued employment. Each option entitles the holder to subscribe for one new share in BioInvent during the period from the day of release of the company’s year-end report for the financial year 2026 up to and including 28 February 2028. The subscription price per share shall be SEK 34.23 

Options granted will vest by 1/3 during each of the financial years 2024, 2025 and 2026, based on performance and continued employment with, or assignment for, BioInvent. The performance criteria for vesting will be based on the same criteria as for management’s annual bonus, which principally are based on fixed technical milestone-criteria in projects, criteria for development of the project portfolio and other pre-determined criteria attributable to the business. 

To enable the company’s delivery of shares pursuant to the option program and to secure costs connected therewith, primarily social security charges, the AGM resolved on a directed issue of maximum of 1,032,400 warrants, and approval of transfer of warrants. If fully exercised, Option Program 2024/2026 will represent a dilution of 1.0 percent of the shares in the Company. Vesting in 2024 amounted to 205,945 options. Vesting in 2025 amounted to 171,191 options. As of December 31, 2025, 597,077 stock options were outstanding.

 

Option Program 2025/2027 

The 2025 AGM resolved to approve the Board’s proposal regarding the implementation of a long-term incentive program in the form of an option program comprising all employees and other key persons in the company. The option program comprise a maximum of 980,000 stock options and the participants may be allotted options free of charge based on performance and continued employment. Each option entitles the holder to subscribe for one new share in BioInvent during the period from the day of release of the company’s year-end report for the financial year 2027 up to and including 28 February 2029. The subscription price per share shall be SEK 40.33. 

Options granted will vest by 1/3 during each of the financial years 2025, 2026 and 2027, based on performance and continued employment with, or assignment for, BioInvent. The performance criteria for vesting will be based on the same criteria as for management’s annual bonus, which principally are based on fixed technical milestone-criteria in projects, criteria for development of the project portfolio and other pre-determined criteria attributable to the business. 

To enable the company’s delivery of shares pursuant to the option program and to secure costs connected therewith, primarily social security charges, the AGM resolved on a directed issue of maximum of 1,136,800 warrants, and approval of transfer of warrants. If fully exercised, Option Program 2025/2027 will represent a dilution of 1.3 percent of the shares in the Company. Vesting in 2025 amounted to 204,756 options. As of December 31, 2025, 746,124 stock options were outstanding.